Study of Seraprevir in Combination With Sofosbuvir in Chronic Genotype 1 Hepatitis C Virus Infection Patients
Status:
Unknown status
Trial end date:
2019-11-30
Target enrollment:
Participant gender:
Summary
This study was to assess the safety and efficacy of Seraprevir in combination with sofosbuvir
administered for 12 weeks in patients with Hepatitis C (HCV) genotype1. Efficacy was assessed
by the rate of sustained viral response (SVR) 12 weeks after the discontinuation of therapy
(SVR12).